Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Physical Exertion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Physical Exertion. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2013-003619-24 Sponsor Protocol Number: bolpecocdpde Start Date*: 2014-02-26
    Sponsor Name:Lourdes Lozano-Bailen
    Full Title: Benefits of liquid oxygen in COPD patients without evidence of domiciliary oxygen therapy, presenting desaturation on exertion.
    Medical condition: Moderate to severe COPD patients: FEV1 <70%, FEV1/FVC <70%, TLC> 80% of the reference values (GesEPOC Stadium II-IV/GOLD III-IV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019873-13 Sponsor Protocol Number: 1200/002 Start Date*: 2010-06-07
    Sponsor Name:UCL Cliniques Universitaires Saint Luc
    Full Title: Comparative study of the clinical response and cardiorespiratory endurance in early rheumatoid arthritis patients treated with Tociluzimab or Methotrexate Addendum protocol : Global gene expression...
    Medical condition: early rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001516-11 Sponsor Protocol Number: 201832 Start Date*: 2017-07-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: 201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Ad...
    Medical condition: Adolescent and Adult Subjects with Asthma and Exercise-Induced Bronchoconstriction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001498-25 Sponsor Protocol Number: CRLX030A2301 Start Date*: 2013-09-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled phase IIIb study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure pa...
    Medical condition: Acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SE (Completed) IE (Completed) BG (Completed) HU (Completed) PT (Completed) LT (Prematurely Ended) IT (Completed) CZ (Completed) AT (Completed) EE (Completed) DK (Completed) ES (Completed) LV (Prematurely Ended) NL (Completed) GR (Completed) GB (Completed) PL (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2021-000365-33 Sponsor Protocol Number: CHDR2043 Start Date*: 2021-03-17
    Sponsor Name:Molecular Partners AG
    Full Title: A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-1...
    Medical condition: SARS-CoV-2 infection (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002513-35 Sponsor Protocol Number: CRLX030A3301 Start Date*: 2013-11-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.
    Medical condition: Acute heart failure
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) SK (Prematurely Ended) BE (Completed) PT (Prematurely Ended) BG (Completed) LT (Completed) PL (Prematurely Ended) LV (Prematurely Ended) EE (Completed) FI (Prematurely Ended) SI (Prematurely Ended) GR (Prematurely Ended) ES (Prematurely Ended) HR (Prematurely Ended) DK (Prematurely Ended) IS (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001281-86 Sponsor Protocol Number: CNTO888PUL2001 Start Date*: 2009-01-14
    Sponsor Name:Centocor B.V.
    Full Title: A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in ...
    Medical condition: Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000984-30 Sponsor Protocol Number: 67896062PAH3001 Start Date*: 2024-01-03
    Sponsor Name:Janssen Pharmaceutical K.K.
    Full Title: A Multicenter, Open-label, Phase III Study to Assess the Efficacy, Safety, and Pharmacokinetics of Macitentan in Japanese Pediatric Patients (≥3 months to <15 years) with Pulmonary Arterial Hyperte...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-004507-20 Sponsor Protocol Number: MEIN/11/RAN-HCM/001 Start Date*: 2012-01-19
    Sponsor Name:Menarini International Operations Luxembourg S.A.
    Full Title: RANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUS
    Medical condition: symptomatic hypertrophic cardiomyopathy (SHCM)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003764-27 Sponsor Protocol Number: HS-20-677 Start Date*: 2022-09-20
    Sponsor Name:Camurus AB
    Full Title: A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease
    Medical condition: Polycystic liver disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) DE (Ongoing) BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001946-10 Sponsor Protocol Number: E-RES/35/13-N08 Start Date*: 2014-08-15
    Sponsor Name:Cipla Ltd.
    Full Title: A randomised, single dose, open label, two-period crossover study evaluating bioequivalence of salmeterol xinafoate HFA pMDI 25μg per actuation manufactured by Cipla Ltd, India (test product) with ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006704-27 Sponsor Protocol Number: Bezafibrate Start Date*: 2009-07-17
    Sponsor Name:Neuromuscular Research Unit, Copenhagen University Hospital Rigshopspitalet
    Full Title: Effect of Bezafibrate on muscle metabolism during exercise in patients with fat metabolic disorders in skeletal muscle
    Medical condition: Evaluation of the effect of Bezafibrate on muscle metabolism during exercise in patients with VLCAD and CPT II deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029316 Neuromuscular disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000085-42 Sponsor Protocol Number: LLB-2019-03 Start Date*: Information not available in EudraCT
    Sponsor Name:LABO'LIFE Belgium sprl
    Full Title: Randomized, placebo-controlled, double blind study to evaluate the efficacy of 2LEBV® and 2LXFS® on asthenia in patients with an EBV infection. EBVAST Study
    Medical condition: Epstein-Barr Virus infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10014077 EBV infection LLT
    23.0 100000004862 10014078 EBV infection reactivation LLT
    21.1 100000004848 10056906 EBV antibody positive LLT
    21.0 100000004848 10056907 EBV antigen positive LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008384-10 Sponsor Protocol Number: NIL-CDNP-CT005 Start Date*: 2009-08-24
    Sponsor Name:Nile Therapeutics, Inc.
    Full Title: A MULTI CENTER, SINGLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF INTRAVENOUS CD‐NP IN THE TREATMENT OF PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE (ADHF)
    Medical condition: Acute Decompensated Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064653 Acute decompensated heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021867-34 Sponsor Protocol Number: IC-01-01-5-006 Start Date*: 2011-12-07
    Sponsor Name:Innovacell Biotechnologie AG - Life Science Center Innsbruck
    Full Title: An open, multicenter study to evaluate the urodynamic properties of a local implantation of autologous skeletal muscle-derived cells (SMDCs) in female patients with stress urinary incontinence
    Medical condition: Stress urinary incontinence (SUI) in female patients with predominantly intrinsic sphincter deficiency of moderate severity (Grade 2 and Grade 3)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003501-15 Sponsor Protocol Number: 408-C-1403 Start Date*: 2015-03-05
    Sponsor Name:Reata Pharmaceuticals, Inc.
    Full Title: A PHASE 2 STUDY OF THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF RTA 408 IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY
    Medical condition: Mitochondrial myopathy as evidenced by the following 2 criteria (must meet both): a. Have a history of exercise intolerance with or without weakness and/or progressive exercise intolerance (in whi...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000107-17 Sponsor Protocol Number: EAT2TREAT Start Date*: 2013-05-22
    Sponsor Name:Hospital of the University of Munich, Grosshadern
    Full Title: Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of 4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM)
    Medical condition: Familial episodic ataxia (EA) represents a genetically and phenotypically diverse group of rare autosomal dominant hereditary disorders characterized by episodes of imbalance and incoordination tha...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10067447 Episodic ataxia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005131-40 Sponsor Protocol Number: MA29957 Start Date*: 2016-10-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIb, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF SILDENAFIL ADDED TO PIRFENIDONE IN PATIENTS WITH ADVANCED IDIOPATH...
    Medical condition: "Pulmonary Hypertension in patients with Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Completed) BE (Completed) DE (Completed) GR (Completed) HU (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002321-29 Sponsor Protocol Number: MK-7264-042 Start Date*: 2020-02-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
    Full Title: A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence
    Medical condition: Chronic Cough and Stress Urinary Incontinence
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10066656 Chronic cough LLT
    20.0 10038359 - Renal and urinary disorders 10066218 Stress urinary incontinence PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000344-21 Sponsor Protocol Number: MP1032-CT05 Start Date*: 2021-06-24
    Sponsor Name:MetrioPharm AG
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PROOF-OF-CONCEPT, PHASE IIA STUDY OF MP1032 PLUS STANDARD OF CARE VS STANDARD OF CARE IN THE TREATMENT OF HOSPITALIZED PATIENTS WITH MOD...
    Medical condition: Moderate to severe coronavirus disease 2019 (COVID 19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    23.0 100000004862 10084382 Coronavirus disease 2019 LLT
    23.1 100000004862 10084529 2019 novel coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Ongoing) BG (Completed) IT (Ongoing) RO (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:30:36 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA